Martha Pritchett Mims MD Ph.D.

Oncology•Houston, TX

Hematologic Oncology

Professor and Section Chief, Hematology & Oncology, Baylor College of Medicine

Join to View Full Profile

1504 Taub LoopDept of MedicineHouston, TX 77030
Phone+1 713-873-2000

Education & Training

Baylor College of MedicineFellowship, Hematology and Medical Oncology, 2003 - 2004
Baylor College of MedicineFellowship, Hematology and Medical Oncology, 2001 - 2003
Baylor College of MedicineResidency, Internal Medicine, 1999 - 2002
Baylor College of MedicineInternship, Internal Medicine, 1998 - 1999
Baylor College of MedicineClass of 1998

Certifications & Licensure

TX State Medical License 2001 - 2026
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases Start of enrollment: 2004 Jan 01
Completed
Phase 3
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
Completed
Phase 3
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
ACTIVE_NOT_RECRUITING
PHASE3
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma Start of enrollment: 2007 Nov 01
Completed
Phase 1
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma Start of enrollment: 2008 Jul 28
ACTIVE_NOT_RECRUITING
PHASE3
Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy Start of enrollment: 2008 Jun 15
Completed
Phase 3
S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2009 May 01
Completed
Phase 2
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia Start of enrollment: 2009 Dec 10
Completed
Phase 2
A Study of Bevacizumab to Prevent Malignant Ascites Start of enrollment: 2009 Jul 01
Withdrawn
Phase 2
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Start of enrollment: 2010 Sep 01
Completed
Phase 2
S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2009 Jul 15
Terminated
Phase 3
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Start of enrollment: 2010 Feb 15
Completed
Phase 3
Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas Start of enrollment: 2010 Oct 06
Completed
Phase 1, Phase 2
GOAT; Phase I Open Label Study of CGTG-102, a GM-CSF Encoding Oncolytic Adenovirus, for Advanced Cancers
Withdrawn
Phase 1
Study of Metformin With Simvastatin for Men With Prostate Carcinoma Start of enrollment: 2012 Jan 01
Withdrawn
Phase 2
Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide Start of enrollment: 2013 Feb 01
Terminated
Phase 1
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
Completed
Phase 3
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia Start of enrollment: 2014 May 19
ACTIVE_NOT_RECRUITING
PHASE3
Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer Start of enrollment: 2014 Jun 01
Terminated
Phase 1
International Registry for Men With Advanced Prostate Cancer (IRONMAN) Start of enrollment: 2017 Jul 21
RECRUITING
Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer Start of enrollment: 2019 May 23
RECRUITING
PHASE2
Roles: Contact, Principal Investigator, Sponsor-Investigator
Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population Start of enrollment: 2020 Dec 22
Recruiting
Phase 2
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
RECRUITING
PHASE1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

2 citations
Development and validation of FinTox: A new screening tool to assess cancer-related financial toxicity.
Hoda Badr, Jessie Han, Martha Mims
Cancer Medicine. 2024-08-01
2 citations
Bringing CAR T cell therapy trials to underserved populations.
Hoda Badr, Rayne Rouce, Michael E Scheurer, Premal Lulla, Martha Mims
Cancer Cell. 2023-12-11
Incidental detection of FGFR3 fusion via liquid biopsy leading to earlier diagnosis of urothelial carcinoma.
Quillan Huang, Irene Mitsiades, Heidi Dowst, Neda Zarrin-Khameh, Attiya Batool Noor
NPJ Precision Oncology. 2023-11-18

Abstracts/Posters

Differential Induction Among Younger Patients Diagnosed with Secondary Acute Myelogenous Leukemia Is Feasible By Cytogenetic/Molecular Risk Stratification
Martha P. Mims, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
SWOG 1312 Final Results: A Phase 1 Trial of Inotuzumab in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Relapsed/ Refractory CD22+ Acute Leukemi...
Martha P. Mims, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Superior Outcome in Elderly AML Patients Receiving Adjuvant Serotonin-Reuptake-Inhibitors during Induction
Martha P. Mims, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Safety Analysis of Five Randomized Controlled Studies of Daratumumab in Patients with Multiple Myeloma
Martha P. Mims, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Who Really Needs a Work-up for Hereditary Thrombophilia?
2019 ACP Internal Medicine Meeting, Philadelphia - 4/12/2019

Press Mentions

Cancer Treatment Study in Harris County Aiming to Bring More Patients Access to Life-Saving CareFebruary 21st, 2025
Harris Health System Receives Elite Commission on Cancer AccreditationFebruary 10th, 2022
Baylor Receives More Than $20 Million in CPRIT FundingAugust 19th, 2021
Join now to see all

Grant Support

OPTIMISE: A Shared Care Approach for Improving Comprehensive Care of Cancer Patients with Comorbidities in A Safety-Net SystemBAYLOR COLLEGE OF MEDICINE2021–2027
OPTIMISE: A Shared Care Approach for Improving Comprehensive Care of Cancer Patients with Comorbidities in A Safety-Net SystemBAYLOR COLLEGE OF MEDICINE2021–2027
Clinical Trials Support UnitNational Cancer Institute2007–2011
Dmt1:Tissue Specific Expression &Alternative SplicingNational Institute Of Diabetes And Digestive And Kidney Diseases2005–2006
Dynamics Of APOE Binding To Lipoproteins And ReceptorsNational Heart, Lung, And Blood Institute1993–1997
Studies Of Cholesteryl Ester Rich LipoproteinsNational Heart, Lung, And Blood Institute1985–1987

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Martha Pritchett Mims MD Ph.D.

Dr. Mims is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Grant Support

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.